173 related articles for article (PubMed ID: 25703642)
41. The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.
Brown MP; Long GV
Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl S3():1-15. PubMed ID: 24712861
[TBL] [Abstract][Full Text] [Related]
42. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
[TBL] [Abstract][Full Text] [Related]
43. Nevoid hyperkeratosis of the areola with histopathological features mimicking mycosis fungoides.
Roustan G; Yus ES; Simón A
Eur J Dermatol; 2002; 12(1):79-81. PubMed ID: 11809604
[TBL] [Abstract][Full Text] [Related]
44. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.
Jhaveri KD; Sakhiya V; Fishbane S
JAMA Oncol; 2015 Nov; 1(8):1133-4. PubMed ID: 26182194
[TBL] [Abstract][Full Text] [Related]
45. Nevoid hyperkeratosis of the nipple and areola: a diagnosis of exclusion.
Sengül N; Parlak AH; Oruk S; Boran C
Breast J; 2006; 12(4):383-4. PubMed ID: 16848855
[No Abstract] [Full Text] [Related]
46. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
47. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
48. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
Forschner A; Zips D; Schraml C; Röcken M; Iordanou E; Leiter U; Weide B; Garbe C; Meier F
Melanoma Res; 2014 Oct; 24(5):512-6. PubMed ID: 24743051
[TBL] [Abstract][Full Text] [Related]
49. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
[TBL] [Abstract][Full Text] [Related]
50. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
[TBL] [Abstract][Full Text] [Related]
51. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
West ES; Williams VL; Morelli JG
Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
[TBL] [Abstract][Full Text] [Related]
52. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
53. Crusted nipple and areola: A new aetiology of secondary hyperkeratosis of the nipple and areola.
Alenizi DA
Indian J Dermatol Venereol Leprol; 2019; 85(2):169-170. PubMed ID: 29491192
[TBL] [Abstract][Full Text] [Related]
54. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib.
Peuvrel L; Ruellan AL; Thillays F; Quereux G; Brocard A; Saint-Jean M; Aumont M; Drouet F; Dreno B
Eur J Dermatol; 2013; 23(6):879-81. PubMed ID: 24192487
[TBL] [Abstract][Full Text] [Related]
55. Facial spiny follicular hyperkeratosis induced by vemurafenib.
Nieto Rodríguez D; Gómez Fernández C; Rueda Carnero JM
J Dermatol; 2018 Feb; 45(2):e43-e44. PubMed ID: 28971523
[No Abstract] [Full Text] [Related]
56. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
[TBL] [Abstract][Full Text] [Related]
57. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
58. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
59. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
60. RASopathic skin eruptions during vemurafenib therapy.
Rinderknecht JD; Goldinger SM; Rozati S; Kamarashev J; Kerl K; French LE; Dummer R; Belloni B
PLoS One; 2013; 8(3):e58721. PubMed ID: 23516541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
